Bevacizumab for paradoxical worsening treatment adjunct in HIV patient with choroidal tuberculoma

Sahil Jain, Priya Bajgai, Basavaraj Tigari, Kusum Sharma, Aman Sharma, Vishali Gupta and Ramandeep Singh*

Abstract

The use of anti-tubercular therapy (ATT) along with anti-retroviral therapy (ART) in human immunodeficiency virus-tuberculosis (HIV-TB) co-infected individuals could at times lead to paradoxical worsening due to an increase in the inflammatory activity due to immune reconstitution inflammatory syndrome (IRIS) in the eye. This is characterized by anterior and posterior segment inflammatory reactions which may occur in the form of serous retinal detachment. We describe a case where the use of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agent led to resolution of the serous retinal detachment, which had failed to respond to other common modalities of treatment.

An HIV-TB co-infected 18-year-old, male patient, who was started on ART and ATT developed IRIS in the form of worsening of serous retinal detachment around a pre-existent asymptomatic tuberculoma. The patient was initially treated with oral and topical steroids without a satisfactory response. Intravitreal bevacizumab was then tried for this patient. Serial fundus photos and optical coherence tomography (OCT) taken before and after treatment showed complete resolution of the serous retinal detachment with two doses of intravitreal bevacizumab. Intravitreal anti-VEGF agents may have a role in the reversal of serous retinal detachment, which occurs as a part of IRIS in HIV-tuberculosis co-infected individuals who have been started on anti-tubercular and anti-retroviral therapies.

Keywords: HIV-TB co-infection, IRIS, Serous retinal detachment, Bevacizumab, Immune recovery uveitis

Introduction

TB is one of the most common opportunistic infections in HIV patients; however, ocular TB in HIV patients is relatively rare. It can occur in the form of anterior or posterior uveitis, most commonly in the form of choroidal granulomas [1, 2]. We initiate anti-tubercular therapy (ATT) and anti-retroviral therapy (ART), following which most of the patients improve but some may develop paradoxical reactions to this therapy. Paradoxical reactions are defined as worsening of the disease after starting of the appropriate therapy, which may be seen with the use of either ATT or ART in both HIV positive as well as negative individuals [3–5]. Topical and oral steroids have been often used in the treatment of this condition [6, 7].

We describe a case of serous retinal detachment that developed around an asymptomatic, pre-existent, tuberculoma as a complication of paradoxical worsening of IRIS, who was successfully treated with intravitreal bevacizumab.

Case report

An HIV infected 18-year-old, male patient, with newly diagnosed sputum smear negative pulmonary TB and CD4 count of 22 cells/μl presented to us for routine ophthalmic examination, without any ocular complaints. The patient was not on ATT or ART at the time of presentation. On examination, his visual acuity was 20/20 in both eyes, and a quiescent anterior chamber. The fundus examination of the right eye showed a well-defined choroidal tuberculoma of 1.5 disc diameter in size in the posterior pole close to the inferior arcade, not involving the fovea (Fig. 1a) and without vitritis or cystoid macular
edema (Fig. 2a). The patient was started on ATT by pul-
monologist and 2 weeks later on ART. Five weeks later, he
came with complaints of decreased vision in the right eye.
His vision was 20/120 in the right eye and 20/20 in the left
eye. On examination of the right eye, the patient had mild
vitritis along with increase in the size and fluid around the
tuberculoma (Fig. 1b). Optical coherence tomography
(OCT) showed foveal serous retinal detachment with fluid
around the enlarged tuberculoma (Fig. 2b). FFA was done
which showed pooling of dye around the lesion in the pos-
terior pole. Internist opinion was sought, and the patient
was put on 1 mg/kg oral prednisolone acetate which was
given in a tapering dose over a period of 3 months. There
was no change in the lesion at 2 weeks. Since there was
no improvement, we decided to opt for another mode of
treatment in the form of anti-VEGF because of its ability
to decrease the vascular permeability. Vitreous tap was
taken during injection, which tested positive for TB-PCR.

After two doses of anti-VEGF, the patient had improved
visual acuity 20/40. The subretinal fluid had totally disap-
peared on OCT (Fig. 2c), and there was also a decrease in
the granuloma size (Fig. 1c). The patient has been followed
up for 12 months following the intravitreal bevacizumab in-
jection, and he has had no fluid or recurrence since then.
Discussion

Even though HIV infected individuals are at a very great risk for systemic TB, ocular TB is relatively rare. Ocular TB may cause features of anterior or posterior uveitis, amongst which tubercle granuloma is the commonest presentation [1, 2]. ATT is often initiated along with ART to treat the disease, following which most of the patients improve, but some patients may develop paradoxical reactions to therapy [3]. This occurs as the body is able to restore its capacity to mount an inflammatory response against either infectious or non-infectious antigens. The infectious agents implicated are mycobacteria, varicella zoster, herpes viruses, and cytomegalovirus [4].

Ocular paradoxical reactions are associated with decrease in vision, floaters and vitritis, worsening of the original lesion, cystoid macular edema, development of new lesions, and serous retinal detachment as was seen in our patient. CD 4 T cell count has found not to be associated with paradoxical reactions. Corticosteroids have been used to treat the condition [5–7]; thus, we initially tried steroids for him which failed to show any response in our patient. Thus, we sought for an alternative therapy for him. One report [8] has used intravitreal bevacizumab to correct serous retinal detachment, and this also has shown to cause regression of the tuberculosis granuloma size [9, 10].

Bevacizumab (Avastin; Genentech, Inc, South San Francisco, CA, USA) is a humanized monoclonal antibody against VEGF. We used intravitreal bevacizumab in two doses at 1 month apart for our patient, and there was a marked improvement in both the functional and anatomical outcomes without any deterioration in the next 12 months of follow-up period. In our case, reversal of the vascular permeability by intravitreal bevacizumab played a role in the reversal of the serous retinal detachment. Phase II trials of bevacizumab in HIV patients state that in well-controlled HIV patients, bevacizumab can be given safely, but data on immune-deficient individuals is still awaited and so its use in low CD4 counts remain questionable [11].

Primary treatment for ocular TB remains steroids with ATT in non-HIV patients. But in HIV patients, ATT alone is given without oral steroids and ART is started at 2- to 3-week interval. With the advent of ART, there has been increased incidence of IRIS during the phase of immune recovery. ATT has also solely shown to cause IRIS, even in immune-competent patients. Treatment guidelines for paradoxical IRIS syndrome in HIV are empirical. Our patient developed IRIS in the form of increased serous fluid after being initiated on ATT and ART, and we document its resolution with intravitreal bevacizumab.

Acknowledgements

None.

Funding

Nil.

Authors’ contributions

SJ, PB, and BT conceived the manuscript, performed literature review, data collection, and analysis, and participated in the management of the case. KS and AS participated in the laboratory diagnosis of the case and in the clinical case management. RS and VG provided the concept and design, were involved in the management of the case, provided intellectual content, and revised the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

An informed consent was taken from the patient.

Received: 25 August 2016 Accepted: 28 October 2016

Published online: 08 November 2016

References

1. Babu RB, Sudarshan S, Kumarasamy N et al (2006) Ocular tuberculosis in acquired immunodeficiency syndrome. Am J Ophthalmol 142:413–418
2. Sudarshan S, Kaleemunnisha S, Banu AA et al (2013) Ocular lesions in 1,000 consecutive HIV-positive patients in India: a long-term study. J Ophthalmic Inflamm Infect 3:2
3. Kumarasamy N, Chaguturu S, Mayer KH et al (2004) Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr 37:1574–1576
4. Shellbum SA III, Hamil RJ, Rodriguez-Barradas MC et al (2002) Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 81:213–227
5. Arevalo JF, Mendoza AJ, Ferretti Y (2003) Immune recovery uveitis in AIDS patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy in Venezuela. Retina 23:495–502
6. Henderson HW, Mitchell SM (1999) Treatment of immune recovery vitritis with local steroids. Br J Ophthalmol 83:540–545
7. Karavellas MP, Azen SP, MacDonald JC et al (2001) Immune recovery vitritis and uveitis in AIDS: clinical predictors, sequence, and treatment outcomes. Retina 21:1–9
8. Cruz MR, Espinosa E, Romero K et al (2011) Bevacizumab reverts serous retinal detachment caused by tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 25:1241–1242
9. Bansal R, Beke N, Sharma A, Gupta A (2013) Intravitreal bevacizumab as an adjunct in the management of a vascular choroidal granuloma. BMJ Case Rep 6:201
10. Babu K, Murthy PR, Murthy KR (2010) Intravitreal bevacizumab as an adjunct in a patient with presumed vasularised choroidal tubercular granuloma. Eye (Lond) 24:397–9
11. Uldrick TS, Wylvill KM, Kumar P et al (2012) Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. J Clin Oncol 30:1476–83